Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Breast 1

Conditions

Multiple Myeloma 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Breast Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × balixafortide × Clear all
NCT01837095 2018-09-14

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

Polyphor Ltd.

Phase 1 Completed
54 enrolled
Breast

Breast Neoplasms

NCT01413568 2016-02-26

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

Polyphor Ltd.

Phase 1/2 Completed
38 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01105403 2014-04-23

Exploratory Study on POL6326 in Stem Cell Mobilization

Polyphor Ltd.

Phase 2 Completed
21 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡